TerminatedNCT01122927

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolarity I, Manic or Mixed Episode With or Without Psychotic Features.

This study has public registry information. It focuses on bipolarity and currently lists study information in Bulgaria, Croatia, Hungary, India, Malaysia, the Philippines, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine, and the United States.

BipolarityOtherFrom 10 Years to 17 Years

In plain English

Key information made simple

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand whether this type of care can give earlier or clearer feedback during care. For people living with Bipolarity, being understood earlier and more clearly can shape the whole care journey. If the findings are useful, they could lead to earlier recognition and more informed decisions later on. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a lab, with sites including Study Site in Dothan, Study Site in Downey, and Study Site in Miami. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Public study data

Key study information

Condition: Adolescent Schizophrenia; Child or Adolescent Bipolarity I, Manic or Mixed Episode With or Without Psychotic Features
Study status: Terminated
Sponsor / lead affiliation: Otsuka Pharmaceutical Development & Commercialization, Inc.
Location / country: Bulgaria, Croatia, Hungary, India, Malaysia, Philippines, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine, United States
Registry: ClinicalTrials.gov

Why this study may matter

This study may matter because it adds public evidence around bipolarity. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Study reference: NCT01122927. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.

In practice

For you

Taking part may help improve understanding of your condition.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Bulgaria.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Main activity: unknown
Intervention: Not available
Time commitment: long follow-up or multiple visits
Study phase: Not available
Enrollment: Not available
Recruitment status: Terminated
Source: Official registry link

FAQ

Questions about this study

What is Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolarity I, Manic or Mixed Episode With or Without Psychotic Features.?

This study is exploring a mental health research question for people with bipolarity. The research team can explain what participation involves. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company. Otsuka is a pharmaceutical company within the Otsuka group, with work across prescription medicines and healthcare products. The sponsor is based in Japan. Sponsor website: https://www.otsuka.co.jp/en/. You can verify the sponsor and study responsibility in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve unknown, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.